ClinicalTrials.gg
RecruitingNCT07001436Updated Jun 3, 2025

A Pharmacokinetics and Safety Study of Azvudine Tablets in Subjects With Mild-To-Moderate GFR Decline in Renal Insufficiency and in Healthy Subjects

A Phase 1 interventional study of Azvudine tablets in Renal Insufficiency, sponsored by Henan Genuine Biotech Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-03.

Sponsored by Henan Genuine Biotech Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 61 studies in Renal Insufficiency with a site in China — 16 open to participants now, 16 under way, none of them phase 3. Renal Insufficiency · China.

Planned enrollment
25th of 48
40 · median 41
Started
2025
with 2 others
Phase 1
22 of 61
4 open now
Primary completion
2025-08
later than 2 of 15 live
Registered
47th of 61
by date

Among the 61 studies in Renal Insufficiency with a site in China, this one is the 25th largest by planned enrollment of the 48 interventional ones that give a count, is one of 3 that started in 2025, is one of 22 in phase 1, reaches primary completion later than 2 of the 15 other live ones, and was the 47th registered.

Renal Insufficiency

1,412 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

16 of the 61 studies in Renal Insufficiency with a site in China are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Renal Insufficiency with a site in China, or all of them as a file.
02

Study summary

Azvudine(FNC),a nucleoside reverse transcriptase inhibitor, make itself a better candidate to be co-formulated in other anti-HIV therapies, thus to improve patient's compliance. FNC is a broad-spectrum RNA virus inhibitor that inhibits the novel coronavirus RNA-dependent RNA polymerase.

This trial uses a non-randomized, open-label, parallel, single-dose adaptive design aimed at investigating the effects of varying degrees of renal insufficiency on the pharmacokinetics, safety, and tolerability of a single oral dose of 3 mg Azvudine tablets in humans. On the first day of the study, a single oral dose of 3 mg ( 3 tablets ) of Azvudine tablets is taken orally on an empty stomach. Biological sample collection and safety examination will be performed in this trial.

03

Conditions studied

  • Renal Insufficiency

Browse trials for

Keywords

  • Azvudine
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

(一) Renal insufficiency study participants and healthy study participants:

  1. Age ≥ 18 years old and ≤ 70 years old, regardless of gender;
  2. (BMI) within the range of 18.0-30.0 (including the critical value) (BMI = weight (kg) / height 2 (m2)), the weight of men should be ≥ 50.0kg, and the weight of women should be ≥ 45.0kg;
  3. Females of must have taken reliable and highly effective measures and have a negative baseline blood pregnancy test at screening, and are willing to use appropriate and efficient methods of contraception after signing the form until 3 months after the last dose of the test drug; Male study participants who are willing to do so for the duration of the trial and for 3 months after the last dose of the trial drug Have no plans to have children and voluntarily use highly effective contraception, or have been surgically sterilized;
  4. Understand and sign the informed consent form.

(二) Health study participants (in addition to the above criteria, they should also meet):

  1. The health condition is judged by the investigator to be good, and the results of vital signs, physical examination, , and laboratory examination are normal or abnormal, and there is no clinical significance;
  2. Those who have not taken any prescription drugs, over-the-counter drugs, Chinese herbal medicines, or health care products within 14 days before screening;
  3. Meet the classification standard of of 90≤GFR\<130 ml/min;
  4. Study participants with mild or moderate decline in GFR were matched with the following demographic characteristics: age (mean ± 10 years), weight (mean ±10kg), and gender (±1 cases).

(三) Renal insufficiency study participants (in addition to the above criteria, they should also meet):

  1. Stable renal function status: the existing renal function impairment is required to last for more than 3 months, and the GFR results of two tests (with an interval of 72 hours or more) during the screening period are within the same grade and the difference between the two tests is not more than 25%;
  2. No abnormalities were found in the pre-test medical history, vital signs, physical examination, laboratory test items (except and AST, total , and direct bilirubin) and test-related examinations and were judged by the clinical research physician to be eligible for enrollment (except for abnormalities related to renal impairment);
  3. The drug being taken by the study participant with renal insufficiency, which should not affect the absorption, distribution, metabolism or excretion of the study drug, and has been taken at a stable dose for at least 4 consecutive weeks before giving the study drug, and agrees to continue treatment during the study period;
  4. Two weeks before administration and during the test, Chinese patent medicines, traditional Chinese medicine decoctions, ethnic medicines, SGLT-2i, MRA drugs and benzbromarone are prohibited;
  5. During the screening period, it is necessary to meet: alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), and direct bilirubin (DBIL) all need to \< 1.5 (ULN)
  6. Participants in the study of renal insufficiency of all grades met the grading criteria for glomerular filtration rate (GFR was taken as the average of the two tests during the screening period): Mild decrease in GFR: 60≤ GFR≤89 ml/min; Moderate decrease in GFR: 30≤GFR ≤59 ml/min.

Exclusion criteria

Exclusion Criteria:

(一) Renal insufficiency and health research participants:

  1. Allergies, especially those who are allergic to any of the ingredients in this product and ;
  2. Those who have undergone gastrointestinal resection in the past, or suffer from digestive diseases that will affect the absorption, distribution, metabolism and excretion of drugs;
  3. Those who have a history of drug abuse within 12 months before screening or those who have tested positive for addictive substances before enrollment;
  4. Those with fever or infectious diseases at the time of screening;
  5. Those who have participated in other clinical trials within 3 months before screening;
  6. Those who have a history of smoking addiction within 12 months before screening (the average number of cigarettes per day ≥5);
  7. Those who have a history of alcohol abuse within 12 months before screening (drinking ≥ 14 units of alcohol per week: 1 unit = 285mL of beer, or 25mL of spirits, or 150mL of wine) or positive alcohol breath test (test value >0mg/100mL) before enrollment;
  8. Those who have lost blood or donated 200mL of blood ≥ within 8 weeks before screening;
  9. surface antigen, virus antibody, antibody, treponema pallidum antibody or rapid plasma reagin ring card test (RPR) test results are positive.
  10. Pregnant and lactating women;
  11. Those who cannot tolerate vascular puncture blood collection and/or have a history of blood sickness, needle fainting and/or poor blood collection vascular conditions;
  12. Those who have been vaccinated within 3 months before screening, or plan to be vaccinated during the trial;
  13. Those who are not considered suitable to enter this trial by the investigator.

(二) Renal insufficiency study participants (except for the above criteria):

  1. Have undergone kidney transplantation;
  2. Systolic blood pressure outside the range of 90 \~ 160mmHg, diastolic blood pressure outside the range of 50 \~ 100mmHg, or heart rate outside the range of 50 \~ 120bpm;
  3. Frequent occurrence of hypoglycemia and exclusion of drug factors within 3 months prior to screening;
  4. Albumin\<30g/L;
  5. value\<9 g/dL;
  6. Those who have a history of uncontrolled or unstable serious diseases of cardiovascular, liver, pulmonary, digestive tract, nerves, , metabolic and musculoskeletal systems, hematopoietic systems and other systems, or those whose diseases are active.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Group 1 : subjects with mildly decreased GFR(GRF, Glomerular Filtration Rate)

    Drug: Azvudine tablets

  • Experimental
    Group 2 : subjects with a moderate decrease in GFR

    Drug: Azvudine tablets

  • Experimental
    Group 3 : healthy subjects matched with group 1 and group 2

    Drug: Azvudine tablets

Interventions

  • On the first day of the study, a single oral dose of 3 mg ( 3 tablets ) of Azvudine tablets is taken orally on an empty stomach.

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Azvudine

    Cmax will be calculated by measuring the concentration of Azvudine in blood samples and urine samples.

    Time frame: Blood samples: up to 48 hours post-dose; urine samples:up to 72 hours post-dose

  2. Pharmacokinetics (PK): Area Under the Concentration-Time Curve from the First Dose to the Last Blood Collection Point (AUC0-t) of Azvudine

    AUC0-t will be calculated by measuring the concentration of Azvudine in blood samples and urine samples.

    Time frame: Blood samples: up to 48 hours post-dose; urine samples:up to 72 hours post-dose

  3. Pharmacokinetics (PK): Area Under the Concentration-Time Curve Extrapolated from the Initial Administration to Infinity (AUC0-∞) of Azvudine (if applicable)

    AUC0-∞ will be calculated by measuring the concentration of Azvudine in blood samples and urine samples.

    Time frame: Blood samples: up to 48 hours post-dose; urine samples:up to 72 hours post-dose

Secondary outcomes

  1. Pharmacokinetics (PK): Time to Maximum Concentration (Tmax) of Azvudine

    Tmax will be calculated by measuring the concentration of Azvudine in blood samples and urine samples.

    Time frame: Blood samples: up to 48 hours post-dose; urine samples:up to 72 hours post-dose

  2. Pharmacokinetics (PK): Elimination Half-life (t1/2) of Azvudine

    t1/2 will be calculated by measuring the concentration of Azvudine in blood samples and urine samples.

    Time frame: Blood samples: up to 48 hours post-dose; urine samples:up to 72 hours post-dose

  3. Occurrence of Adverse Events

    Clinical presentation characteristics, severity, onset time, duration of adverse events, management measures, outcomes, and the correlation with the investigational drug.

    Time frame: From enrollment to the end of the study on Day 4.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Aug 2025, 3 months after the start.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 3 months is below that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2025
First posted
Jun 3, 2025
StartActual
May 20, 2025
Primary completionEst.
Aug 30, 2025
CompletionEst.
Sep 30, 2025
Last update
Jun 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07001436
Lead sponsor
Henan Genuine Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Jun 3, 2025
Start date
May 20, 2025
Primary completion
Aug 30, 2025 (estimated)
Completion
Sep 30, 2025 (estimated)
Last update
Jun 3, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azvudine

Start the discussion